- Social Responsibility
- Social Responsibility
- Our Giving
- Corporate Social Responsibility
- Be The First Tobacco-Free Generation
- Community Stories
- Thought Leadership
- Investor Story
- Results Center
- 2016 In Review
- Financial Information
- SEC Filings
- Events & Presentations
- Stock Information
- Corporate Governance
- Investor Resources
PharmaCare Included in Genzyme's Thyrogen(R) Distribution Network
Thursday, April 21, 2005
LINCOLN, R.I., April 21 /PRNewswire-FirstCall/ -- PharmaCare, a subsidiary of CVS Corporation (NYSE: CVS), announced today that its specialty pharmacy division, PharmaCare Specialty Pharmacy, has been selected by Genzyme to be a national distributor of its drug Thyrogen(R) (thyrotropin alfa for injection), a diagnostic tool in the management of patients with well-differentiated thyroid cancer.
"We're extremely proud to have been chosen by Genzyme for the distribution of Thyrogen(R)," said Greg Weishar, president and CEO of PharmaCare. "Our significant history as a specialty pharmacy, and unique patient outreach programs, allow us to help people living with thyroid cancer to receive this important medication efficiently and to get the support and information they need to use it successfully."
PharmaCare Specialty Pharmacy was selected as a national network provider for Thyrogen(R) because of its reputation for high quality customer service. PharmaCare Specialty Pharmacy serves patients with complex pharmaceutical needs, and offers a variety of advanced services such as medication adherence monitoring, expert medication counseling, drug interaction monitoring, reimbursement assistance and patient counseling and education programs.
The American Cancer Society estimates that approximately 26,000 new cases of thyroid cancer will be diagnosed this year. Although thyroid cancer is one of the most treatable forms of cancer, it requires a lifetime of careful monitoring and testing. As one of the world's leading biotechnology companies, Genzyme has been committed to helping patients with well-differentiated thyroid cancer since the 1980s. Using Thyrogen(R), in combination with common imaging and laboratory tests, helps to increase the sensitivity of the testing while allowing patients to avoid the potentially adverse effects of thyroid hormone withdrawal. It is estimated that over 160,000 patients worldwide have used Thyrogen(R) to date.
"Our relationship with PharmaCare, as one of the select group of providers we've chosen, ensures both patients and physicians will have their Thyrogen(R) prescription needs fulfilled by a reputable, patient focused organization," said Heidi Gautier, Vice President of U.S. Sales for Thyrogen(R).
PharmaCare is one of the largest pharmaceutical benefit management companies in the country. PharmaCare helps large employers, managed care organizations, insurance companies, unions and government agencies make safe, cost effective drug decisions for over 30 million Americans. The company's comprehensive PBM services include fully integrated, state-of-the art mail- service pharmacies and one of the largest specialty operations in the country. PharmaCare fills prescriptions at more than 56,800 retail pharmacies, located in all 50 states, and in nearly every city. PharmaCare is a wholly owned subsidiary of CVS Corporation (NYSE: CVS).
About Genzyme Corporation
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $2 billion and nearly 7,000 employees in locations spanning the globe. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.